DUBLIN - May 5th, 2015 - Aalto Bio Reagents is pleased to announce availability of our partially purified cell culture derived IgE (Aalto code AU3296). IgE is a member of the immunoglobulin family of proteins that was first described in the 1960’s. IgE, like all immunoglobulins, is produced by plasma cells in response to antigenic stimuli. IgE is unique however in certain structural aspects and the role it plays in allergic diseases. Measurement of total serum IgE is often used as a tool in the diagnosis and management of atopic diseases such as asthma, hay fever, atopic dermatitis and urticaria. It has been used to distinguish atopic from non-atopic individuals presenting allergy-like symptoms. In addition, studies have also shown that increased levels of IgE in cord blood and infants may be predictive of future atopic tendencies.
Normal levels of circulating IgE are extremely low in comparison to other immunoglobulins. Levels of IgE at birth are almost undetectable but increase in non-allergic adults. Elevated levels are commonly seen in cases of allergic diseases, parasitic infections, pulmonary aspergillosis, Wiskott-Aldrich syndrome, and myeloma. Myeloma IgE serum has been the raw material of choice for many years for manufacturers of IgE control and calibrators. Locating this natural product can be challenging and often companies are forced to hold large volumes in stock or face potential out of stock situation.
Compared to native myeloma plasma, Aalto Bio Reagents’ cell culture derived product has the distinct advantage of always being available. The material is derived from a human myeloma cell line which means that lot to lot consistency is guaranteed without having to worry about relying on a donor and all of the concerns that can accompany a natural product.
For further information contact: firstname.lastname@example.org
For direct product information: